智通财经APP讯,心玮医疗-B(06609)发布公告,本集团开发的自膨式颅内药物洗脱支架的注册申请已获中国国家药品监督管理局(国家药监局)受理。
自膨式颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗,对狭窄和梗阻的管腔具有支撑和开通的作用,并且能有效预防支架内的管腔再狭窄。根据公开信息查询,目前全球范围内尚无类似产品获批上市,本公司对该类型产品的研发进度处于行业内领先水平。
智通财经APP讯,心玮医疗-B(06609)发布公告,本集团开发的自膨式颅内药物洗脱支架的注册申请已获中国国家药品监督管理局(国家药监局)受理。
自膨式颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗,对狭窄和梗阻的管腔具有支撑和开通的作用,并且能有效预防支架内的管腔再狭窄。根据公开信息查询,目前全球范围内尚无类似产品获批上市,本公司对该类型产品的研发进度处于行业内领先水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.